GLQ223 + zidovudine

GLQ223 + zidovudine is a **combination therapy** explored for the treatment of HIV infection. **Zidovudine** (also known as azidothymidine or AZT) is a nucleoside analog reverse-transcriptase inhibitor (NRTI) that works by inhibiting the enzyme reverse transcriptase, thereby blocking HIV replication[3]. **GLQ223** is an experimental immunomodulatory agent investigated in the early 1990s as part of HIV combination regimens; preclinical data suggested it could potentially enhance immune responses but its exact molecular mechanism remains poorly defined in peer-reviewed literature. Combination regimens like GLQ223 + zidovudine were studied to evaluate their impact on immune function, viral load, and tolerability compared to zidovudine alone.

Other names

azidothymidine + GLQ223